Sex Differences in the Impact of Aortic Valve Calcium Score on Mortality After Transcatheter Aortic Valve Replacement.


Journal

Circulation. Cardiovascular imaging
ISSN: 1942-0080
Titre abrégé: Circ Cardiovasc Imaging
Pays: United States
ID NLM: 101479935

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 4 8 2022
medline: 19 8 2022
entrez: 3 8 2022
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR) is now an approved alternative to surgical aortic valve replacement for the treatment of severe aortic stenosis. As the clinical adoption of TAVR expands, it remains important to identify predictors of mortality after TAVR. We aimed to evaluate the impact of sex differences in aortic valve calcium score (AVCS) on long-term mortality following TAVR in a large patient sample. We included consecutive patients who successfully underwent TAVR for treatment of severe native aortic valve stenosis from June 2010 to May 2021 across all US Mayo Clinic sites with follow-up through July 2021. AVCS values were obtained from preoperative computed tomography of the chest. Additional clinical data were abstracted from medical records. Kaplan-Meier curves and Cox-proportional hazard regression models were employed to evaluate the effect of AVCS on long-term mortality. A total of 2543 patients were evaluated in the final analysis. Forty-one percent were women, median age was 82 years (Q1: 76, Q3: 86), 18.4% received a permanent pacemaker following TAVR, and 88.5% received a balloon expandable valve. We demonstrate an increase in mortality risk with higher AVCS after multivariable adjustment ( We demonstrate a notable sex difference in the association between AVCS and long-term mortality in a large TAVR patient sample. This study highlights the potential value of AVCS in preprocedural risk stratification, specifically among women undergoing TAVR. Additional studies are needed to validate this finding.

Sections du résumé

BACKGROUND
Transcatheter aortic valve replacement (TAVR) is now an approved alternative to surgical aortic valve replacement for the treatment of severe aortic stenosis. As the clinical adoption of TAVR expands, it remains important to identify predictors of mortality after TAVR. We aimed to evaluate the impact of sex differences in aortic valve calcium score (AVCS) on long-term mortality following TAVR in a large patient sample.
METHODS
We included consecutive patients who successfully underwent TAVR for treatment of severe native aortic valve stenosis from June 2010 to May 2021 across all US Mayo Clinic sites with follow-up through July 2021. AVCS values were obtained from preoperative computed tomography of the chest. Additional clinical data were abstracted from medical records. Kaplan-Meier curves and Cox-proportional hazard regression models were employed to evaluate the effect of AVCS on long-term mortality.
RESULTS
A total of 2543 patients were evaluated in the final analysis. Forty-one percent were women, median age was 82 years (Q1: 76, Q3: 86), 18.4% received a permanent pacemaker following TAVR, and 88.5% received a balloon expandable valve. We demonstrate an increase in mortality risk with higher AVCS after multivariable adjustment (
CONCLUSIONS
We demonstrate a notable sex difference in the association between AVCS and long-term mortality in a large TAVR patient sample. This study highlights the potential value of AVCS in preprocedural risk stratification, specifically among women undergoing TAVR. Additional studies are needed to validate this finding.

Identifiants

pubmed: 35920157
doi: 10.1161/CIRCIMAGING.122.014034
pmc: PMC9397521
mid: NIHMS1823358
doi:

Substances chimiques

Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e014034

Subventions

Organisme : NICHD NIH HHS
ID : K12 HD065987
Pays : United States

Références

JAMA. 1992 Sep 16;268(11):1417-22
pubmed: 1512909
JACC Cardiovasc Interv. 2018 Feb 26;11(4):395-403
pubmed: 29471953
Am J Cardiol. 2018 May 15;121(10):1225-1230
pubmed: 29706182
JACC Cardiovasc Imaging. 2012 May;5(5):469-77
pubmed: 22595154
Circulation. 2004 Jul 20;110(3):356-62
pubmed: 15249504
Circ Cardiovasc Imaging. 2013 Jan 1;6(1):40-7
pubmed: 23233744
Circ Cardiovasc Qual Outcomes. 2018 Jun;11(6):e004713
pubmed: 29853466
Heart. 2017 Oct;103(20):1619-1624
pubmed: 28698175
Mayo Clin Proc. 2019 Aug;94(8):1457-1466
pubmed: 30824280
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Cardiovasc Comput Tomogr. 2017 Mar - Apr;11(2):87-96
pubmed: 28139364
Am J Cardiol. 2020 Oct 15;133:98-104
pubmed: 32843145
JACC Cardiovasc Imaging. 2016 Apr;9(4):499-501
pubmed: 27056168
JACC Cardiovasc Interv. 2021 May 10;14(9):952-960
pubmed: 33865734
Heart. 2015 Feb;101(3):209-14
pubmed: 25301859
Circulation. 2010 Sep 14;122(11 Suppl):S23-8
pubmed: 20837918
Int J Cardiol. 2013 Jul 1;166(3):652-7
pubmed: 22197118
J Am Coll Cardiol. 2014 Sep 23;64(12):1202-13
pubmed: 25236511
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005363
pubmed: 30879326
Int J Cardiol Heart Vasc. 2015 Oct 31;9:95-99
pubmed: 28785716
J Am Coll Cardiol. 2012 Sep 4;60(10):882-6
pubmed: 22818068
J Cardiovasc Comput Tomogr. 2014 Mar-Apr;8(2):131-40
pubmed: 24661826
Can J Cardiol. 2018 Aug;34(8):992-998
pubmed: 30056851
J Am Coll Cardiol. 2016 Dec 27;68(25):2733-2744
pubmed: 28007135
Interv Cardiol Clin. 2015 Jan;4(1):23-37
pubmed: 28582120
J Am Coll Cardiol. 2012 Feb 7;59(6):566-71
pubmed: 22300690
JACC Cardiovasc Interv. 2021 Jan 25;14(2):115-134
pubmed: 33478630
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
J Cardiovasc Echogr. 2020 Apr-Jun;30(2):88-92
pubmed: 33282646
Circ Cardiovasc Imaging. 2018 Mar;11(3):e007146
pubmed: 29555836
Circulation. 1992 Oct;86(4):1099-107
pubmed: 1394918
Int J Cardiol. 2020 May 1;306:20-24
pubmed: 32139241
Curr Probl Cardiol. 2021 Mar;46(3):100694
pubmed: 33039143
Nat Rev Cardiol. 2018 Jan;15(1):57-65
pubmed: 28836620
AJR Am J Roentgenol. 2006 Feb;186(2):342-9
pubmed: 16423936
Methods Inf Med. 1993 Nov;32(5):382-7
pubmed: 8295545
Circ Cardiovasc Imaging. 2022 Jan;15(1):e013165
pubmed: 34983195
Eur Heart J. 2016 Feb 21;37(8):693-9
pubmed: 26508159
JACC Cardiovasc Interv. 2015 Apr 27;8(5):645-53
pubmed: 25946435
JACC Cardiovasc Interv. 2018 Mar 26;11(6):581-589
pubmed: 29566805

Auteurs

Parth P Patel (PP)

Mayo Clinic Alix School of Medicine, Jacksonville, FL (P.P.P.).

Abdallah El Sabbagh (A)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Patrick W Johnson (PW)

Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL (P.W.J., R.E.C.).

Rayan Suliman (R)

Mayo Clinic Alix School of Medicine, Jacksonville, FL (P.P.P.).

Najiyah Salwa (N)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Andrea Carolina Morales-Lara (AC)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Peter Pollak (P)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Mohamad Yamani (M)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Pragnesh Parikh (P)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Sushilkumar K Sonavane (SK)

Department of Radiology, Mayo Clinic, Jacksonville, FL (S.K.S.).

Carolyn Landolfo (C)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Mohamad Adnan Alkhouli (MA)

Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.A.A., M.F.E., M.G., P.A.N.).

Mackram F Eleid (MF)

Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.A.A., M.F.E., M.G., P.A.N.).

Mayra Guerrero (M)

Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.A.A., M.F.E., M.G., P.A.N.).

F David Fortuin (FD)

Division of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ (F.D.F., J.S.).

John Sweeney (J)

Division of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ (F.D.F., J.S.).

Peter A Noseworthy (PA)

Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.A.A., M.F.E., M.G., P.A.N.).

Rickey E Carter (RE)

Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL (P.W.J., R.E.C.).

Demilade Adedinsewo (D)

Division of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (A.E.S., N.S., A.C.M.-L., P.P., M.Y., P.P., C.L., D.A.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH